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Abstract
Variants in the SPATA5 gene were recently described in a cohort of patients with global developmental delay, sensorineural
hearing loss, seizures, cortical visual impairment and microcephaly. SPATA5 protein localizes predominantly in the
mitochondria and is proposed to be involved in mitochondrial function and brain developmental processes. However no
functional studies have been performed. This study describes ﬁve patients with psychomotor developmental delay,
microcephaly, epilepsy and hearing impairment, who were thought clinically to have a mitochondrial disease with
subsequent whole-exome sequencing analysis detecting compound heterozygous variants in the SPATA5 gene. A summary
of clinical data of all the SPATA5 patients reported in the literature conﬁrms the characteristic phenotype. To assess
SPATA5’s role in mitochondrial dynamics, functional studies were performed on rat cortical neurons. SPATA5-deﬁcient
neurons had a signiﬁcant imbalance in the mitochondrial fusion-ﬁssion rate, impaired energy production and short axons. In
conclusion, SPATA5 protein has an important role in mitochondrial dynamics and axonal growth. Biallelic variants in the
SPATA5 gene can affect mitochondria in cortical neurons and should be considered in patients with a neurodegenerative
disorder and/or with clinical presentation resembling a mitochondrial disorder.
Introduction
Autosomal recessive variants in the SPATA5 (spermato-
genesis-associated protein 5, MIM: 613940) gene were
recently associated with a speciﬁc disease phenotype.
Tanaka et al. [1], Kurata et al. [2] and Buchert et al. [3]
reported 25 individuals with intellectual disability,
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Functional studies of SPATA5 deﬁciency 409
microcephaly, hypotonia, spasticity, seizures, sensorineural
hearing loss and cortical visual impairment.
The SPATA5 gene and the protein encoded by it were
ﬁrst described by Liu et al. [4] as a spermatogenesis-
associated factor (SPAF). The SPAF protein is a member of
the AAA (ATPase Associated with diverse Activities)
protein subfamily having two highly conserved ATPase
modules and a putative mitochondrial matrix-targeting
sequence. Liu et al. [4] concluded that SPATA5 gene may
be important in spermatogenesis, through remodelling of
mitochondria from an orthodox form to a condensed form,
as SPAF’s predominant expression was in the spermato-
gonia and spermatocytes, but not in spermatids, and sub-
cellularly in the inner membrane and matrix of
mitochondria. However, no functional studies to link var-
iants in the SPATA5 gene to mitochondrial dysfunction have
been done. In addition, the recent association of SPATA5
variants with a neurodegenerative disease [1–3], suggests a
role of the SPATA5 gene not only in spermatogenesis, but
also in neuronal development.
This paper reports ﬁve new patients from four families
with compound heterozygous variants in the SPATA5 gene
and reviews the clinical features and reported mutations of
all the patients described so far.
To analyse the pathomechanisms of SPATA5 gene deﬁ-
ciency on a cellular level, functional studies on rat cortical
neurons were undertaken. An association with neuronal
development and mitochondrial dysfunction is suggested.
Patients
Five patients from four different families were enroled in
this study. The ﬁrst family with two affected individuals
(Patients 1 and 2) was identiﬁed at the Department of
Clinical Genetics, Tartu University Hospital, Tartu, Estonia.
Three other families with single affected cases (Patients 3, 4
and 5) were detected at the Institute of Human Genetics,
Technical University Munich, Germany. The detailed
information about the patients is given in Table 1 and in the
Supplementary File. Common features for all the patients
were global developmental delay, moderate microcephaly,
myoclonic/tonic–clonic epilepsy, abnormal EEG, brain
atrophy and/or delayed myelination (Supplementary Fig.
S1A–D), sensorineural hearing loss, hyperreﬂexia, spasti-
city and dystonia. The facial phenotype of Patient 3 is
illustrated on Supplementary Fig. S1E, F. The patients were
suspected clinically to have a mitochondrial disorder.
However, screening analyses for metabolic disorders
including mitochondrial diseases from blood, urine and
cerebrospinal ﬂuid were mostly unremarkable. Mitochon-
drial respiratory chain enzyme analyses from muscle
showed combined defects of complex I and IV in Patient 5,
but were normal in Patient 1 (from cultured skin ﬁbroblasts)
and Patient 3 (from muscle). Whole-exome sequencing
(WES) was performed in Patients 1, 3, 4 and 5 in the
context of two separate research projects.
Methods
The study of the Estonian family was approved by Research
Ethics Committee of the University of Tartu (approval date
17/11/2014 and number 242/M-10). The ethics committee
of the Technical University Munich approved the study of
Patients 3, 4 and 5.
Whole-exome sequencing
WES analysis of the Patients 1, 3, 4 and 5 was carried out
using methods described earlier [5, 6] and detected com-
pound heterozygous variants in the SPATA5 gene. All the
variants were submitted to the LOVD (http://databases.lovd.
nl/shared/genes/SPATA5) with individual IDs 00103212-
00103215.
Functional studies
To analyse the functional consequences of SPATA5 gene
deﬁciency on the central nervous system, the effects of
SPATA5 shRNA silencing on rat cortical neurons were
investigated using the following methods.
Plasmids
Plasmids expressing scrambled shRNA or shRNA targeted
against rat SPATA5 were obtained from SABiosciences
and were previously validated by PCR. Plasmids
expressing GW1-PercevalHR (49082) and neuron-speciﬁc
pAAV-hSyn-DsRedExpress (22907) were obtained from
Addgene. Mito-KikGR1 was constructed as described ear-
lier [7].
Neuronal cultures
Primary cultures of rat cortical cells were prepared from
neonatal Wistar rats as described [8]. Neurons were grown
in Neurobasal A medium supplemented with B27 with or
without Phenol Red on poly-L-lysine-coated 96-well white
plates, 35-mm plastic or glass bottom dishes. All culture
media and supplements were obtained from Life Sciences.
For transfection of cells growing on glass bottom dishes, the
conditioned medium was replaced with 100 μl Opti-MEM I
medium containing 2% Lipofectamine 2000 and 1–2 μg
total DNA containing an equal amount of each plasmid. The
410 S. Puusepp et al.
dishes were incubated for 3–4 h, after which fresh medium
was added.
Mitochondrial fusion and ﬁssion rate analysis
For mitochondrial fusion and ﬁssion rate analysis, cortical
neuronal cultures were transfected with mito-KikGR1
plasmid and plasmids of interest as described earlier [7]
and examined at DIV 7–8 by a laser scanning confocal
microscope (LSM 780, Carl Zeiss Microscopy GmbH). For
fusion acquisition, mito-KikGR1 was illuminated with a
488-nm argon laser line to visualize the intense green
mitochondrial staining. Selected mitochondria were then
photoconverted to red using a 405-nm diode laser and
illuminated using a 561 nm DPSS laser. The images were
taken at 10-s intervals for 10 min, the fate of all activated
mitochondria was followed throughout the time-lapse, and
the fusion and ﬁssion events were recorded.
ATP/ADP ratio measurement
Neurons expressing the ATP/ADP ratio sensor PercevalHR
at neuronal endings were excited using a 405 nm diode laser
and a 488 nm line of an Argon laser and collected using a
494–553 nm emission window. The ratio of ﬂuorescence
intensities, when exciting at 488 nm divided by 405 nm
(F488 nm/F405 nm), was calculated from the collected
signal from 50 axonal endings from ﬁve dishes per group.
Axonal growth
For neuronal maturation experiments, cortical neurons were
transfected at day 1 in vitro (DIV1) with a plasmid
expressing neuron-speciﬁc pAAVhSyn-DsRed1 and plas-
mids of interest. For the analysis of axonal growth, images
of cultured cortical neurons at DIV4 were captured using an
Olympus IX70 inverted microscope with a 20x objective
and traced manually using Neurolucida software (MBF
Bioscience) and Fiji [9].
Immunohistochemistry
Neurons, HeLa, COS7 and SHSY5Y cells were ﬁxed using
4% paraformaldehyde solution in NeurobasalTM A con-
taining 5% sucrose for 10 min at 37 °C. Fixed cells were
permeabilised using 0.1% Triton X-100 in PBS for 7 min
and then blocked using 10% normal goat serum and 3%
BSA for 60 min at room temperature. The cells were then
incubated with the primary antibodies rabbit anti-myc
(1:300, ab 9106, Abcam, USA) and mouse anti-TOM20
(1:200, ab 56783, Abcam, USA) in the presence of 10%
normal goat serum and 3% BSA at 4 °C for 24 h. After
washing, the cells were further incubated with respective
Alexa-Fluor-488- or Alexa-Fluor-594-conjugated second-
ary antibodies at room temperature for 1 h and subsequently
examined using confocal microscope.
Statistics
Data are presented as the mean ± SEM. T-test or one-way
ANOVAs followed by Bonferroni post hoc test were used
to compare differences between experimental samples and
control groups. P values of <0.05 were considered statisti-
cally signiﬁcant.
Results
Whole-exome sequencing
In Patient 1, after ﬁltering for rare protein altering possibly
biallelic variants two heterozygous variants in the SPATA5
gene were identiﬁed by WES: c.250C>T, p.(Arg84*) and
c.989_991del, p.(Thr330del) (RefSeq NM_145207.2). The
c.250C>T is a nonsense variant presumably causing loss-of-
function, which appears only in 1 out of 121,318 alleles
(i.e. one heterozygous carrier) in the Exome Aggregation
Consortium (ExAC) database [10]. The c.989_991del in-
frame deletion has been previously reported in multiple
patients with SPATA5-related disorder [1–3]. Both variants
were conﬁrmed by Sanger sequencing in both, Patients 1
and 2. Their mother was conﬁrmed to carry only the
c.250C>T variant, DNA from the father was not available
for testing.
In Patient 3, after ﬁltering the results of WES with the
frequency of online databases (MAF < 0.1% in 1000 gen-
omes, ExAC), pathogenicity prediction programs (Poly-
Phen-2, Sift) and ClinVar, SPATA5 was the only gene with
both variants predicted to be probably damaging
(c.554G>A, p.(Gly185Glu)) or having a likely pathogenic
rating in ClinVar (c.989_991del, p.(Thr330del)). The
compound heterozygous state of the two variants was
conﬁrmed by Sanger sequencing, the mother carried the
missense variation, the father the deletion.
WES analysis of Patient 4, using the above-described
ﬁltering, identiﬁed only SPATA5 gene containing a non-
sense loss-of-function heterozygous variant, namely
c.394C>T, p.(Gln132*). The patient also carried the
c.989_991del, p.(Thr330del) in-frame deletion in hetero-
zygous state in the SPATA5 gene. The mother was the
carrier of the nonsense variant and the deletion came from
the father.
The same ﬁltering method of Patient 5 resulted in only
one nonsense loss-of-function variant (c.700C>T, p.
(Gln234*)) in the SPATA5 gene. This variant was detected
in a heterozygous state predicted to be compound
Functional studies of SPATA5 deﬁciency 411
heterozygous with the c.2384C>G, p.(Pro795Arg) missense
variant. This assumption was conﬁrmed by Sanger
sequencing, where the healthy mother was the carrier of the
c.700C>T nonsense variant and the healthy father carried
the c.2384C>G missense variant, each in heterozygous
state.
Patient 1 was identiﬁed in the Estonian research project,
which included 21 patients with a clinical suspicion of a
mitochondrial disorder, but no genetic diagnosis. These 21
cases were selected from a database of 181 patients whose
ﬁbroblast cell cultures have been stored from 2003-2014.
Patients 3–5 were identiﬁed in the German research project,
which included 353 patients with a suspicion of a mito-
chondrial disorder to whom WES analysis was performed
and the three patients with SPATA5 variants were identiﬁed.
Fig. 1 SPATA5 has a
dominantly cytosolic
localization and does not co-
localize with mitochondria.
Overexpressed SPATA5–myc
(detected using an anti-myc
antibody, green) is showing
relatively homogenous
localization in cortical neurons,
SH-SY5Y and Hela cells. In
COS7 cells, part of the SPATA5
was in ﬁlamentous network-like
structures but as demonstrated
by the zoom panels it was
nevertheless not co-localizing
with mitochondria.
Mitochondrial outer membrane
was stained using TOM20
antibody
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The diagnostic yield was 0.6% and 0.8% in those two
cohorts, respectively.
The results of the functional studies on rat cortical
neurons
SPATA5 is cytosolic and not co-localizing with the
mitochondrial marker
SPATA5 protein has a putative mitochondrial matrix-
targeting sequence and has been shown to localize in
mitochondria in mouse testis [4]. However, subcellular
localization data of SPATA5 in neurons and other cell types
has not been reported. To our surprise the localization of
overexpressed SPATA5 in cultured primary cortical neu-
rons was dominantly cytosolic and clearly not co-localizing
with the mitochondrial marker (Fig. 1). Similar relatively
homogenous cytosolic localization was observed in neuro-
nal SH-SY5Y cells and HeLa cells. The signal was less
homogenous in COS7 cells, but also clearly not co-
localizing with the mitochondrial marker. Unfortunately,
we were not able to visualize endogenous SPATA5 as the
antibody staining was too weak for co-localization study. It
should also be noted that despite having the mitochondrial
targeting sequence, several subcellular localization predic-
tion tools like PSORT II [11], Yloc [12] and Cello [13]
suggested cytosolic localization of SPATA5.
SPATA5 deﬁciency affects mitochondrial morphology and
inhibits mitochondrial dynamics
Previously, it has been suggested that SPATA5 has a role in
mitochondrial morphogenesis during spermatogenesis [4].
Therefore, we ﬁrst tested whether the SPATA5 deﬁciency
affects mitochondrial morphology in neurons. Indeed, there
was a signiﬁcant, 20% decrease in mitochondrial length in
SPATA5 shRNA-treated neurons (efﬁciency of
SPATA5 shRNA is demonstrated in Fig. 2a) compared with
scrambled shRNA-treated controls (Fig. 2b, c). The
Fig. 2 SPATA5 deﬁciency impairs mitochondrial dynamics and ATP
production. a Relative mRNA expression levels in neuronal PC cells
transfected with scrambled or SPATA5 shRNA. The expression level
of SPATA5 was normalized to CYC. b, c Neurons were transfected
with mito-DsRed, GFP and scrambled shRNA or SPATA5 shRNA.
SPATA5 shRNA neurons demonstrate signiﬁcantly reduced mito-
chondrial length (n= 16 neurons in each group). d–g Primary cortical
neurons were transfected with the photoconvertible mitochondrially
targeted construct mito-Kikume—Green and scrambled shRNA or
SPATA5 shRNA. Selected mitochondria were irradiated using a 405-
nm laser line, thereby converting mito-Kikume—Green into mito-
Kikume—Red. Fusion events between mito-Kikume—Green and
photoactivated mito-Kikume—Red mitochondria are visible when
mitochondria become yellow after mixing of the contents of the red
and green mitochondria (white arrows) and ﬁssion events when these
mitochondria split (yellow arrows) (d). In primary cortical neurons,
SPATA5 shRNA tends to decrease the fusion rate (e) and increase the
ﬁssion rate (f) leading to signiﬁcant decrease in fusion–ﬁssion ratio (g)
(four ﬁelds per dish were imaged and at least four dishes per condition
were used). h–i Neurons were transfected with the ATP sensor Per-
ceval and scrambled SPATA5 shRNA or SPATA5 shRNA plus
shRNA insensitive human SPATA5 encoding plasmid. FRET (F488),
CFP (F405) and pseudocolour ratiometric (F488/F405) images of an
axonal ending of control neuron expressing PercevalHR are depicted
(h). SPATA5-deﬁcient neurons show a lower cytosolic ATP level as
compared to the control (i). Note that the lower ATP levels in SPATA5
deﬁcient neurons is restored by wt SPATA5 overexpression (n= 50
neurons)
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mitochondrial length is controlled by mitochondrial
fusion–ﬁssion balance [7]. Therefore, we then measured
mitochondrial fusion and ﬁssion using photoconvertible
mitochondria targeted Kikume Green-Red, which enables the
quantiﬁcation of fusion events between green- and red-
emitting mitochondria (Fig. 2d). There was a slight statisti-
cally non-signiﬁcant decrease in the number of fusion events
in SPATA5 shRNA-treated neurons and slight statistically
non-signiﬁcant increase in the number of ﬁssion events in
SPATA5 shRNA-treated neurons (Fig. 2e, f). However,
together these changes led to two fold statistically signiﬁcant
decrease in fusion–ﬁssion ratio suggesting strong imbalance
between the fusion and ﬁssion events in neuronal axons
(Fig. 2g).
SPATA5 deﬁciency is associated with decreased cellular ATP
To test whether the changes in mitochondrial morphology
and dynamics could affect the energetic status of the neu-
rons a quantitative analysis of cell ATP/ADP ratio was
performed using the genetically encoded ﬂuorescent ratio-
metric probe PercevalHR, which senses ATP/ADP ratio
(Fig. 2h) [14]. Neurons were ﬁrst transfected with
SPATA5 shRNA encoding plasmid and compared with
scrambled shRNA-treated controls. Further experiments
performed at axonal endings of scrambled or
SPATA5 shRNA expressing neurons showed a statistically
signiﬁcant 12% decrease in signal in the SPATA5 shRNA
group, suggesting a decrease in ATP levels (Fig. 2i).
Overexpression of human shRNA-insensitive SPATA5
restored the ATP/ADP ratio in the SPATA5 shRNA-treated
group demonstrating the speciﬁcity of shRNA.
SPATA5 deﬁciency delays neuronal development
The results demonstrate that SPATA5 deﬁciency delayed
the development of cortical neurons markedly. The longest
axon was signiﬁcantly shorter in developing DIV4 SPATA5
shRNA-transfected neurons (Fig. 3). Similarly, over-
expression of human shRNA-insensitive SPATA5 restored
the axonal growth in the SPATA5 shRNA-treated group.
Discussion
Including these 5 subjects, 30 patients with homozygous or
compound heterozygous variants in the SPATA5 gene have
been reported in the literature [1–3]. All patients share
similar features and thus a characteristic phenotype can be
described.
Symptoms start in early infancy with all of the patients
developing global developmental delay with severely lim-
ited speech or no words, hearing impairment (most
frequently sensorineural hearing loss, 77%), and a patho-
logical EEG with symptomatic epilepsy being present in
73% of patients. Other prominent features are microcephaly
(90%), gastrointestinal problems (73%), abnormal brain
MRI (67%, predominantly brain atrophy and delayed
myelination), visual impairment (most frequently cortical
visual impairment, 41%) and no or reduced eye contact
(48%). The patients tend to have a combination of axial
hypotonia and peripheral hypertonia with spasticity.
Detailed clinical data of all reported patients is summarized
in Table 2.
Together, 25 different variants have been found across
the gene: 14 missense, 5 nonsense, 3 frameshift variants, 2
in-frame deletions and 1 intronic splice-site variant. These
are illustrated in Fig. 4. The most common reported variant
is an in-frame deletion (c.989_991del, p.(Thr330del)) that
was seen in 6 out of 18 different families (33%) and in 8 of
the 30 patients. Three other variants (p.(Arg84Gln); p.
(Arg186*); p.(Asp628Gly)) have occurred in two different
families each. Interestingly, there is a homozygous indivi-
dual with the p.(Thr330del) variant in the ExAC database
[10], but also one patient described by Tanaka et al. [1] has
a homozygous p.(Thr330del) variant. There are no mutation
hot spots in the gene and there is no clear association
between the location of the variants and severity of the
phenotype. The siblings in Tanaka et al. [1] underlie this
fact, as the younger sister has a milder phenotype than her
elder brother, although they have the same genotype
(NM_145207.2: c.2351G>A and c.269G>T). The precise
investigation of the 3D structure of the protein could help
for better understanding of the effects of the variants.
Previous researchers have suggested that SPATA5 is
associated with mitochondrial morphology and function [4].
This study shows that SPATA5 deﬁcient neurons have a
signiﬁcant imbalance of mitochondrial fusion and ﬁssion
events leading to mitochondrial shortening that in turn result
in decreased ATP production at axonal endings. This con-
ﬁrms that SPATA5 deﬁciency alters the morphology and
function of mitochondria in neurons and therefore can be
indirectly categorized under mitochondrial disorders. This
also supports the patients’ phenotype and the clinicians’
initial suspicion of a mitochondriopathy.
In contrast to Liu et al. [4] suggesting that SPATA5 is
localized in the inner membrane or matrix of mitochondria
in mouse testis, our experiments in cortical neurons, SH-
SY5Y, Hela and COS7 cells showed that it was dominantly
cytosolic. We observed no co-localization with mitochon-
dria suggesting that the putative mitochondrial targeting
sequence might not be sufﬁcient to drive SPATA5 to the
mitochondria in these cell types. It should be noted here that
Liu et al. [4] did also demonstrate that SPATA5 and the
mitochondrial marker signals do not overlap. There are
many examples where non-mitochondrial proteins play an
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active role in mitochondrial function. These proteins control
mitochondrial biogenesis, mitochondrial trafﬁcking and
anchoring, as well as mitochondrial quality control
mechanisms (e.g. mitophagy).
For example, mitochondrial neurogastrointestinal ence-
phalomyopathy (MNGIE) is caused by variants in the
TYMP gene encoding cytosolic thymidine phosphorylase.
These variants cause loss of thymidine phosphorylase
activity and lead to accumulation of thymidine and deox-
yuridine. This impairs mtDNA replication leading to accu-
mulation of point mutations, deletions, and depletion of
mtDNA [15–17]. Variants in the gene encoding KIF5A
(Kinesin Family Member 5A), a protein that interacts with
mitochondrial adaptor proteins and is responsible for
mitochondrial transport in axons, are leading to hereditary
spastic paraplegia [18, 19]. Variants in Parkin, a cytosolic
ubiquitin E3 ligase known to be a crucial component of
mitochondrial quality control mechanism, are associated
with hereditary Parkinson’s disease [20, 21]. Another Par-
kinson’s disease related protein LRRK2, known to be
involved in the regulation of mitochondrial dynamics and
function, is also primarily localized to the cytoplasm [22].
Variants in the GBA gene encoding lysosomal glucocer-
ebrosidase cause Gaucher disease and increase suscept-
ibility to Parkinson’s disease. Elegant paper by Osellame
et al. [23] shows that this is related to downregulation of
mitophagy and the ubiquitin–proteasome system resulting
in accumulation of dysfunctional and fragmented mito-
chondria leading in turn to impaired energy and free radical
homoeostasis.
The majority of Wolfram syndrome cases are caused by
variants in the WFS1 (Wolfram syndrome 1) gene encoding
an endoplasmic reticulum (ER) protein. However, the
clinical features of the syndrome resemble mitochondrial
disease symptoms [24]. We have recently shown that down-
regulation of WFS1 in neurons leads to dramatic changes in
mitochondrial dynamics (inhibited mitochondrial fusion,
altered mitochondrial trafﬁcking and augmented mito-
phagy), which results in lower levels of ATP and inhibits
neuronal development [25]. Another example of the ER
protein variant responsible for mitochondrial damage is
RYR1 (ryanodine receptor type 1) variant in central core
disease [26]. One of the characteristics of this type of
myopathy is the lack of mitochondria within the centres of
muscle ﬁbres. Therefore, our results allow to suggest that
similarly to these proteins, SPATA5 is indirectly or directly
interacting with mitochondria and required for their proper
dynamics. Nevertheless, we cannot completely exclude a
possibility that a small fraction of SPATA5 is still localized
to the mitochondria and controls the mitochondrial function
from there.
This study also shows that the SPATA5 gene plays an
important role in the development of cortical neurons. Local
ATP supply is critical for axonal growth. In neurons, most
of the ATP supply is produced in the mitochondria and
decline in ATP production could impair the axonal growth.
Depletion of mitochondria at or before axogenesis prevents
axon formation [27]. Similarly, a lack of synaptic or term-
inal axonal mitochondria results in aberrant organelle
transport and dysfunctional synapses [28, 29]. Vaarmann
et al. [30] and Cagalinec et al. [25] have recently shown that
increased mitochondrial ATP production in axonal endings
supports axonal growth and suggests that mitochondrial
Fig. 3 SPATA5 deﬁciency impairs neuronal growth. Primary cortical
neurons were transfected with the neuronal marker pAAV-hSyn-
DsRed1 and scrambled shRNA or SPATA5 shRNA at DIV 1, and
neuronal morphology was assessed at DIV 4. a Microscopy images
(above) and examples of Neurolucida reconstructions (below) are
depicted. b SPATA5 deﬁciency retards growth of the longest axon that
is restored by wt SPATA5 overexpression (n= 30 neurons in each
group)
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ATP production is required for proper neuronal
development.
In conclusion, SPATA5 protein is required to sustain
mitochondrial morphology, dynamics and ATP production
in neurons and its deﬁciency leads to impaired axogenesis
in vitro, in primary cortical neurons. SPATA5 deﬁciency
results in a syndrome with severe global developmental
delay, severe speech impairment, hearing loss, abnormal
electroencephalogram and microcephaly. Biallelic variants
in the SPATA5 gene can affect mitochondria in cortical
neurons and should be considered in patients with a neu-
rodegenerative disorder and/or with clinical presentation
resembling a mitochondrial disorder.
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